# Ablacon, Inc.

- Location (FDA's records): Denver, CO
- FDA decisions: 3 (2021–2023): 3 510(k) clearances
- Product codes: DQK (2), MTD (1)
- 510(k) review time since 2016: median 156 days, against 132 for FDA's reviews in the same codes and years (0 of 3 faster)
- Predicates its devices cite: 4 (1 its own); citations of its devices by later devices: 3 (1 its own)
- Recalls linked to its devices: 0 (0 Class I)
- Data: FDA decisions to Oct 25, 2026; recalls to Oct 12, 2026

## Firms whose devices it cites most
- Abbott Electrophysiology: 2 (https://510kreport.com/company/abbott-electrophysiology)
- Boston Scientific Corp: 1 (https://510kreport.com/company/boston-scientific)

## Firms that cite its devices most
- Boston Scientific Corp: 1 (https://510kreport.com/company/boston-scientific)
- Cortex, Inc.: 1 (https://510kreport.com/company/cortex)

## Its most-cited devices
- K203084: Ablamap Software (2021), cited by 1
- K223666: Ablacath™ Mapping Catheter (2023), cited by 1
- K230008: Ablamap® System (2023), cited by 1

## Recent decisions
- K230008: Ablamap® System (Jun 8, 2023)
- K223666: Ablacath™ Mapping Catheter (Mar 17, 2023)
- K203084: Ablamap Software (Aug 31, 2021)

Source page: https://510kreport.com/company/ablacon